drugset / Trial / NCT00754221

Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia

NCT00754221

Phase 3 Terminated 390 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study to investigate the long-term safety and effectiveness \[S,S\]-Reboxetine in relieving the symptoms of Fibromyalgia in patients.

Timeline

Start
2008-05
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject [S,S]-Reboxetine Unknown 4 mg Oral
Subject [S,S]-Reboxetine Unknown 6 mg Oral
Subject [S,S]-Reboxetine Unknown 8 mg Oral
Subject [S,S]-Reboxetine Unknown 10 mg Oral

Indications